Gaining weight on retatrutide can be alarming, especially given the drug's reputation for significant weight loss in clinical trials. Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon pathways — but individual responses vary, and short-term weight increases are not uncommon. Fluid retention, dose titration phases, metabolic adaptation, dietary habits, and underlying health conditions can all contribute to unexpected weight changes during treatment. This article explains the most likely reasons, when to seek medical advice, and how lifestyle factors can support the drug's effectiveness.

How Retatrutide Works and Its Effect on Body Weight

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that suppresses appetite and may increase energy expenditure, but it is not yet MHRA- or EMA-licensed and individual weight loss responses vary considerably.

Retatrutide is an investigational triple receptor agonist that targets three hormonal pathways simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism distinguishes it structurally from existing licensed treatments such as semaglutide (GLP-1 only) or tirzepatide (GLP-1 and GIP). By activating all three receptors, retatrutide is designed to suppress appetite, and preclinical and early-phase data suggest it may also increase energy expenditure and improve metabolic function — though robust long-term human evidence for the energy expenditure effect remains limited. There are currently no published head-to-head trials comparing retatrutide directly with UK-licensed weight-management agents.

In clinical trials, retatrutide has demonstrated substantial weight loss outcomes. Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) showed average weight reductions of up to approximately 24% over 48 weeks at the highest doses studied, primarily in adults without type 2 diabetes. Weight loss effects may be smaller in people with type 2 diabetes, based on patterns observed with other agents in this class. It is important to note that retatrutide is not yet authorised for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), nor approved by the European Medicines Agency (EMA); it remains under clinical investigation and is not available as a licensed medicine.

Retatrutide should only be used within an approved clinical trial or formal research programme. It should not be sourced from unregulated online vendors or private suppliers, as doing so carries serious safety risks and no regulatory oversight.

Despite promising trial findings, individual responses vary considerably. Not everyone will experience the same degree of weight loss, and some individuals may notice periods where weight does not decrease — or increases slightly. Understanding why this happens requires looking at both the pharmacology of the drug and the broader context of each person's health, lifestyle, and treatment journey.

Common Reasons Weight May Increase During Treatment

Short-term weight increases during retatrutide treatment are most often caused by normal daily fluctuation, fluid retention, constipation, or inadequate appetite suppression during early dose titration rather than treatment failure.

If you are gaining weight whilst taking retatrutide, it is understandably concerning — but there are several plausible explanations that do not necessarily indicate treatment failure.

One of the most common reasons for short-term scale increases is normal day-to-day weight fluctuation. Body weight can vary by 1–2 kg or more within a single day depending on fluid intake, sodium consumption, glycogen stores (which bind water), bowel habits, and clothing. Constipation — a recognised side effect of GLP-1-based therapies — can also temporarily add to measured weight. For this reason, NHS guidance recommends weighing yourself at the same time of day, on the same scales, and under consistent conditions, and tracking trends over weeks rather than days.

Fluid retention can cause transient increases on the scales. Common causes include high dietary sodium intake, hormonal fluctuations related to the menstrual cycle, and changes in carbohydrate intake affecting glycogen and associated water storage. Whilst hormonal shifts during treatment may play a role, the precise mechanisms in the context of retatrutide specifically have not been established in published human data.

Muscle gain is a less common but possible explanation, particularly if you have significantly increased resistance training alongside treatment. Muscle tissue is denser than fat, so body composition may improve even if overall weight appears stable or rises slightly. However, it is worth noting that GLP-1-based therapies can sometimes reduce lean muscle mass alongside fat, particularly without adequate protein intake and resistance exercise — so muscle gain should not be assumed without objective body composition assessment.

Dose titration phases may also play a role. During the early weeks of treatment, when doses are gradually increased to minimise gastrointestinal side effects, appetite suppression may not yet be fully established. Some individuals may eat slightly more during this adjustment period, though direct evidence for compensatory intake during retatrutide titration is limited.

Finally, hormonal fluctuations unrelated to the medication — including those linked to the menstrual cycle, thyroid function, or stress — can cause transient weight changes. Keeping a consistent weight log helps distinguish genuine trends from normal variation.

Factors That Can Slow or Reverse Weight Loss Progress

Metabolic adaptation, calorie-dense dietary choices, alcohol, weight-promoting medicines, and underlying conditions such as hypothyroidism or PCOS can all blunt or reverse weight loss progress during retatrutide treatment.

Several underlying factors can blunt the effectiveness of retatrutide and contribute to weight gain or a plateau during treatment.

Metabolic adaptation is one such factor. As the body loses weight, it naturally adjusts its resting metabolic rate downward in an attempt to preserve energy stores. This is a well-documented physiological response and can make continued weight loss progressively more difficult over time, even with effective pharmacotherapy.

Dietary habits remain critically important. Retatrutide reduces appetite, but it does not eliminate the impact of calorie-dense food choices. If appetite suppression leads to smaller portions of high-calorie, ultra-processed foods rather than a shift towards more nutritious options, overall caloric intake may remain higher than expected. Alcohol consumption is often overlooked — alcoholic drinks are calorie-dense and can stimulate appetite in ways that may counteract the drug's effects.

Medicines associated with weight gain should also be considered. Certain medicines — including corticosteroids, some antidepressants (such as mirtazapine), and antipsychotics — are associated with weight gain and may partially offset the benefits of retatrutide (BNF; NICE CKS). If you are taking any of these, speak to your prescriber about a structured medication review. Do not stop or adjust any prescribed medicine without medical advice. For people with type 2 diabetes, insulin and sulfonylureas carry an additional risk of hypoglycaemia if used alongside retatrutide, and dose adjustments should only be made under close clinical supervision.

Underlying health conditions such as hypothyroidism, polycystic ovary syndrome (PCOS), Cushing's syndrome, and insulin resistance or type 2 diabetes can independently drive weight gain and should be assessed and managed if not already addressed. Your GP can arrange relevant tests — for example, a TSH blood test if hypothyroidism is suspected. If features of Cushing's syndrome are present (such as central weight gain, easy bruising, or stretch marks), an endocrine referral may be appropriate.

Psychological factors such as emotional eating, binge eating disorder, or chronic stress can undermine treatment outcomes. These are recognised clinical barriers to weight management — not personal failings — and may benefit from specialist support alongside pharmacological treatment.

When to Speak to Your Doctor or Prescriber

Seek urgent medical attention for severe abdominal pain, chest pain, or significant swelling; seek prompt advice for unexplained rapid weight gain, new hormonal symptoms, or persistent gastrointestinal side effects affecting nutrition.

Because retatrutide is not yet licensed in the UK, anyone currently taking it should be doing so within a clinical trial or specialist research programme, with a named clinician or research team overseeing their care. That team should be your first point of contact for any concerns about unexpected weight changes or side effects. Clinical trial participants should report any adverse effects promptly to their study team. Suspected side effects from any medicine can also be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Seek urgent medical attention immediately if you experience:

• Severe or persistent abdominal pain, with or without vomiting, fever, or jaundice — these may be symptoms of pancreatitis or gallbladder disease, which are recognised risks with GLP-1-based therapies (see NHS information on pancreatitis and gallstones)

• Chest pain or acute breathlessness, which require emergency assessment

• Significant swelling of the legs, ankles, or abdomen, particularly if accompanied by breathlessness, which may suggest a cardiovascular concern

Seek prompt (non-emergency) medical advice if you notice:

• Unexplained or rapid weight gain — for example, approximately 2 kg or more within 3 days without an obvious dietary cause, or a consistent upward trend over several weeks

• New or worsening symptoms such as persistent fatigue, cold intolerance, hair loss, or irregular periods, which could indicate an underlying thyroid or hormonal condition

• Persistent nausea, vomiting, or abdominal discomfort that is affecting your ability to maintain adequate nutrition

• Mood changes or disordered eating patterns that are affecting your relationship with food

Even outside these specific triggers, if you feel that your treatment is not working as expected after several weeks at a stable dose, a review with your prescriber is entirely appropriate. NICE guidance on obesity management (CG189 and related technology appraisals) emphasises the importance of regular monitoring and individualised care — principles that apply equally to emerging treatments such as retatrutide.

If you are not currently under specialist care and are concerned about your weight, your GP can refer you to NHS Tier 3 or Tier 4 weight-management services, where appropriate multidisciplinary support is available.

Lifestyle Factors That Support Retatrutide's Effectiveness

A diet rich in lean protein, fibre, and minimally processed foods, combined with at least 150 minutes of weekly aerobic activity and resistance training, helps maximise retatrutide's effectiveness and preserve lean muscle mass.

Pharmacological treatment for obesity works best when supported by sustainable lifestyle changes. Retatrutide is not a standalone solution, and the clinical trials that demonstrated its efficacy were conducted alongside dietary and behavioural counselling. Adopting evidence-based lifestyle strategies can help maximise your results and reduce the likelihood of weight gain during treatment.

Dietary quality is arguably the most important modifiable factor. Rather than focusing solely on calorie counting, aim for a diet rich in:

• Lean proteins (chicken, fish, legumes, eggs) — which support satiety and help preserve muscle mass during weight loss, which is particularly important given that GLP-1-based therapies may reduce lean mass alongside fat if protein intake is insufficient

• Fibre-rich vegetables and wholegrains — which slow gastric emptying and complement the drug's appetite-suppressing effects

• Healthy fats (olive oil, avocado, nuts) — in moderate quantities to support hormonal health

• Minimally processed foods — reducing reliance on ultra-processed products that are engineered to override satiety signals

If you have chronic kidney disease or other conditions affecting protein metabolism, speak to your clinical team before significantly increasing protein intake.

Physical activity plays a dual role: it supports energy expenditure and helps preserve lean muscle mass during weight loss. The UK Chief Medical Officers' guidelines (via NHS Live Well) recommend at least 150 minutes of moderate-intensity aerobic activity per week, combined with muscle-strengthening exercises on two or more days. Resistance training is particularly valuable for maintaining lean mass during pharmacological weight loss, as supported by body composition analyses from trials of GLP-1-based agents such as semaglutide and tirzepatide (STEP and SURMOUNT programme substudies).

Sleep quality and stress management are frequently underestimated. Poor sleep elevates ghrelin (the hunger hormone) and reduces leptin (the satiety hormone), directly counteracting the appetite-suppressing effects of retatrutide. Chronic stress similarly drives cortisol-mediated fat storage, particularly around the abdomen. Addressing these factors through sleep hygiene, mindfulness, or psychological support can meaningfully improve treatment outcomes.

What the Current Evidence Says About Long-Term Outcomes

Phase 2 data show substantial short-term weight loss with retatrutide, but long-term evidence beyond 48 weeks is limited; weight regain after discontinuation is anticipated based on patterns seen with other GLP-1-based agents.

Retatrutide is one of the most promising agents in the current pipeline for obesity pharmacotherapy, but it is essential to interpret the available evidence with appropriate context. The Phase 2 trial published in 2023 (Jastreboff et al., New England Journal of Medicine) demonstrated impressive short-term weight loss, but long-term data — particularly beyond 48 weeks — remain limited. Phase 3 trials are ongoing and registered on ClinicalTrials.gov and the EU Clinical Trials Register. Until these are completed and reviewed by regulatory bodies such as the MHRA and EMA, the full picture of long-term efficacy and safety has not yet been established.

One important consideration from existing GLP-1 receptor agonist research is the likelihood of weight regain after discontinuation. The STEP 1 extension study (Wilding et al., 2022) showed that participants regained a significant proportion of lost weight within one year of stopping semaglutide. Based on the shared mechanism, a similar pattern might reasonably be anticipated with retatrutide — though this remains an expectation pending retatrutide-specific long-term data rather than an established finding. This underscores the importance of viewing obesity as a chronic condition requiring long-term management rather than a short-term intervention.

There is currently no evidence from published trials that retatrutide causes sustained or unexplained weight gain in the majority of participants when taken correctly within a trial setting. Instances of weight gain during treatment are more likely attributable to the individual factors outlined in earlier sections than to the drug itself. However, as with all emerging therapies, ongoing trial follow-up and, if approved, post-marketing pharmacovigilance will be essential to fully characterise its benefit-risk profile.

If you are participating in a trial or accessing retatrutide through a research programme, your clinical team will be monitoring outcomes closely. Engaging openly with that process — including reporting unexpected changes in weight or any new symptoms — contributes to the broader evidence base and ensures your own care remains appropriately tailored.

A brief note on pregnancy and breastfeeding: if you are pregnant, planning a pregnancy, or breastfeeding, you must inform your clinical team immediately. Incretin-based therapies are generally avoided during pregnancy pending specific safety data, and your team will advise on appropriate management.

Frequently Asked Questions